Identification of functional pathways mediating molecular responses may lead to better understanding of disease processes and suggest new therapeutic approaches. We introduce a method to detect such mediating functions using topological properties of protein-protein interaction networks. We introduce the concept of pathway centrality, a measure of communication between disease genes and differentially expressed genes. We find mediating pathways for three pulmonary diseases (asthma; bronchopulmonary dysplasia (BPD); and chronic obstructive pulmonary disease (COPD)) using pathway centrality. Mediating pathways shared by all three pulmonary disorders heavily favor inflammatory or immune responses and include specific pathways such as cytokine production, NF Kappa B, and JAK/STAT signaling. Disease-specific mediators, such as insulin signaling in BPD or homeostasis in COPD, are also highlighted. We support our findings, some of which suggest new treatment approaches, both with anecdotal evidence from the literature and via systematic evaluation using genetic interactions.
. We calculate the pathway centrality (PC) score for a candidate pathway S considering only the paths from nodes in D to nodes in E. We then use permutation tests to assess whether S has higher pathway-centrality than expected (see Methods). For each gene set S, the percentage of such random sets with higher pathway centrality scores than S is reported as p cent (S), a rough measure of significance.
In this initial study, we apply our novel pathway-centrality method to three pulmonary diseases that primarily affect patients at different stages of life:
bronchopulmonary dysplasia (BPD), a neonatal complication of preterm birth; asthma, which is relevant across the lifespan but is becoming increasingly common in children;
and chronic obstructive pulmonary disease (COPD), a term that encompasses a number of progressive lung disorders that predominantly affect the elderly (Suzuki et al., 2016) .
We examine mediating pathways in each disease and look for common pathways relating all three.
One caveat is that pathways with low pathway centrality significance (p cent ) scores for multiple diseases might be highly central in the network structure overall, and could appear to be "significant" for any disease considered. Therefore, as a further control, we applied the method to Down syndrome (DS) data, with the understanding that most functions relevant in pulmonary disorders are probably not that relevant to the etiology of DS, although we agree that there may be some exceptions. Our "disease genes" in this case are simply any genes located on chromosome 21, rather than genes that have been directly implicated in the etiology of DS symptoms.
Supplementary Figure S1 shows the overlaps between the four disease gene sets and the four differentially-expressed gene sets. Although there is some overlap between the sets of disease genes, particularly involving genes involved in inflammation and immune response, overall the disease gene sets are reasonably disjoint and the differentially-expressed gene sets even more so. Thus, common pathways across all three networks are unlikely to have arisen from shared shortest paths between identical sets of genes.
Pathway gene sets used in our experiments come from the Biological Process (BP) terms in the Gene Ontology (Ashburner et al., 2000) , pathways in the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et al., 2016) , and mammalian phenotypes (MP) from the International Mouse Phenotyping Consortium in the Mouse Genome Database (Bult et al., 2016) .
Our results show that pathways involved in inflammation or adaptive immunity, and several related signaling pathways including NFKB, JAK/STAT, and toll-like receptor signaling, are common to all three pulmonary disorders. Disease-specific findings include protein homeostasis pathways in COPD, leukocyte chemotaxis in asthma, and regulation of map kinase activity in BPD. While many of our findings have already been proposed as disease mediators, diagnostics, or targets in previous publications, we discovered several novel mediators that may suggest new therapeutic approaches to these pulmonary disorders.
Results and Discussion
Pathway centrality finds mediating pathways and potential drug targets Pathways with significant pathway centrality in specific pulmonary data sets but not in the Down syndrome data include known disease mediators and potential targets.
Full lists of results are available as supplemental data; Table 1 shows the top few pathways implicated in exactly one of the pulmonary disorders. We highlight some of these top pathways here.
Highly significant in asthma is the BP gene set leukocyte chemotaxis. Neutrophil chemotaxis velocity has been suggested as a biomarker for asthma and incorporated into a diagnostic test to distinguish asthma from nonasthmatic allergic rhinitis (Sackmann et al., 2014) . The KEGG gene set cell adhesion molecules tops the list in COPD, pointing at similar processes, although the only genes shared between these two gene sets are ITGB2 and ITGA9. Prior work suggests that adhesion molecules also play a significant role in the pathogenesis of COPD (Ishii, 1999) , and that regulation of adhesion may be a new therapeutic approach for both COPD and asthma (Chen et al., 2008, Woodside and Vanderslice, 2008) . The KEGG pathway tight junction is also implicated in asthma.
Although adhesion and leukocyte chemotaxis are important to all three disorders (Faura Tellez et al., 2016 , Ramsay et al., 1998 , Barnes et al., 2009 , the pathway centrality approach highlights different sets of genes mediating these responses. Different pathways have been implicated in recruitment of neutrophils in different contexts in COPD (Barnes et al., 2009 ), suggesting the plausibility of context-specific variation.
Topping the GO COPD list are two terms relating to homeostasis. Protein homeostatic imbalance has been implicated in the pathogenesis of COPD, although this approach to characterizing the disease has not yet been thoroughly explored (Bodas et al., 2012) . Such imbalances have been successfully targeted through small molecules or gene therapies in other diseases such as cystic fibrosis. Addressing the imbalance of critical NFKB-regulated inflammatory proteins has thus been suggested as a possible therapeutic approach in COPD and other airways diseases (Bouchecareilh and Balch, 2012 , 2010) . There is also evidence that ERK/MAPK activation can protect against the negative effects of hyperoxia on alveolar development and lung epithelial cells (Xu et al., 2006 , Buckley et al., 2005 . Drugs that promote this process have been suggested as potential therapies for BPD (Sakurai et al., 2013) .
The KEGG insulin signaling pathway is also implicated as a mediator in BPD.
The role of insulin signaling in BPD is unclear, but low neonatal serum IGF-1 levels have been shown to be associated with the later development of BPD (Lofqvist et al., 2012) .
This evidence is consistent with cell and animal studies showing that IGF-1 signaling, mediating by NFKB, enhances collagen synthesis in fetal lung fibroblasts (Chetty et al., 2006) , and that IGF-1 and IGFR1 regulate alveologenesis in neonatal rats (Belcastro et al., 2015) . Whether this finding suggests novel strategies for BPD treatment, however, is an open question.
Commonalities across all three pulmonary disorders implicate immune processes and signaling pathways
When we look for pathways that play a significant role across all three pulmonary disorders (Table 2) , we are not surprised to find a preponderance of inflammatory and immune processes. GO terms topping the list implicate the adaptive immune response, cytokine production, and pro-inflammatory NF Kappa B signaling. Recent research implicates IKK-driven NFKB activation of inflammation in both COPD and asthma, but suggests that the different components of the system involved in the two diseases could explain their differing pharmacological responses (Gagliardo et al., 2011) , and could suggest new avenues for therapy. NFKB-mediated inflammation has also been implicated in the pathogenesis of BPD. The increased prevalence of early-onset emphysema in BPD survivors (Wong et al., 2008) supports the hypothesis that an NFKBrelated inflammatory phenotype predisposes individuals to an increased reaction to environmental airway stress (Park et al., 2014) . Links between BPD and asthma through NFKB1A promoter polymorphisms have also been identified (Ali et al., 2013) .
The KEGG and MP gene set collections implicate several more specific pathways, including different types of lymphocyte responses, JAK/STAT signaling, toll-like receptor signaling, and FC Epsilon RI signaling. The JAK/STAT pathway has been suggested as an asthma target through inhibitors of activating cytokines and receptors (Vale, 2016, Weltman and Karim, 1998) . JAK pathway inhibitors are in development for a number of inflammatory disorders (O'Shea et al., 2015) , and animal models have suggested that targeting this pathway can reduce airway hyperresponsiveness, reflecting the potential for such compounds in both COPD and asthma (Barnes, 2016) . The role for JAK/STAT signaling in bronchopulmonary dysplasia is less clear, but it has been suggested that it plays a role in airway smooth muscle mitogenesis, implicated in both asthma and BPD (Simon et al., 2002) , and postulated that it may be an alternative mediator of the oxidative stress response in both diseases (Zhou and Hershenson, 2003) . Thus, our work suggests that the effects of JAK pathway inhibitors may be worth exploring in pre-clinical models of bronchopulmonary dysplasia.
Toll-like receptor (TLR) signaling, which activates the innate immune response, is another familiar part of the story of airway hyperreactivity and fetal lung development (Petrikin et al., 2010) . TLR polymorphisms have been linked to an increased risk of developing BPD (Carrera et al., 2015 , Malash et al., 2016 , and TLR agonists are already being tested for therapeutic efficacy in asthma (Biggadike et al., 2016) . However, the role of this system in COPD is not as clear. Aspects of the innate immune response are often demonstrably suppressed in COPD patients (Shaykhiev and Crystal, 2013) , and TLR polymorphisms play a role in disease susceptibility and severity (Apostolou et al., 2016 , Yu et al., 2016 . Our work therefore also suggests a role for TLR pathways in the diagnosis, stratification, and treatment of COPD.
Finally, the FC Epsilon RI signaling pathway raises interesting questions about common elements of these three diseases. Figure 2 shows a subset of this pathway and the network for BPD. The gene FCER1A is one of the primary receptors for immunoglobulin E (IgE) (Sharma et al., 2014) , the key player in initiating allergic response. The role of allergy in these three disorders, however, is thought to be quite different. The significant impact of IgE response in allergic asthma is well-studied (Gould and Sutton, 2008) . Its role in COPD is less clear. Many patients with COPD but no asthma diagnosis have one or more asthma-like symptoms, including atopy, and there are suggestions that allergic response plays a role in severity for a subset of those with COPD (Suzuki et al., 2016) .
In contrast, most evidence suggests that bronchopulmonary dysplasia is not linked to the development of allergies or to IgE response (Kwinta et al., 2013) . Indeed preterm birth has been shown to correlate with a decreased risk of atopy (Siltanen et al., 2001) , although with an increased risk of asthma and ultimately of obstructive pulmonary disease (Stern et al., 2007) . Further, the question of whether asthma in survivors of BPD is more likely to be non-atopic is still open, although there is some evidence supporting this hypothesis (Verhaeghe et al., 1990 , Ronkainen et al., 2016 . In this context, the fact that this signaling pathway is nonetheless implicated as a mediator of gene expression changes in infants with BPD is intriguing and may shed light on the mechanisms involved in the disease. Perhaps it simply reflects airway hyperreactivity in general, but there is little specific evidence supporting this possibility. Further exploration of this pathway's role in the development of BPD is therefore warranted.
Genetic interaction data confirms the identification of mediating pathways
Finding specific examples consistent with existing knowledge provides anecdotal evidence that an approach is effective, but more systematic evaluation is needed. One indication that the proposed mediating pathways are, at least in some respect, downstream of the disease genes, would be to identify an excess of epistatic relationships between them. For example, if a mediating pathway looks like that shown in Figure 1 Because few such relationships have yet been characterized in humans or other mammals, we assembled a set of putative positive genetic relationships from orthologous genes in yeast, worm, and fly. For a mediating gene set or pathway S and disease gene set D, we determine k, the number of such relationships between genes in D and S. We then use a separate permutation test (see Figure 3 and Methods) to assess the probability of finding k such relationships with a random gene set of size |S|, which we call p med (S).
Overall correlation between p cent (S) and p med (S) varies considerably across the data sets and annotation sets, with a range of 0.07 to 0.74. The lowest correlations come from the Down syndrome data, where this approach is more problematic due to the large number of "disease" (i.e., trisomic) genes that are likely not directly involved in the etiology of the DS phenotype. Instead of overall correlation, however, our goal is to assess the probability that a pathway S having a low p cent (S) value is more likely to have a low p med (S) value as well. We therefore split the range of p cent values up into deciles, and plotted the probability of finding a p med score below 0.05 in each decile. A sample plot of these probabilities is shown in Figure 4 ; the rest are available as supplemental data. If the slope of a linear regression line through the points (the blue line in Figure 4 ) is significantly less than zero, it suggests that the probability of being a mediator is highest for the most significantly central pathways. the highest probability; the poor significance and relatively flat slope occur because there also happen to be many genetic relationships for p cent values above 0.8.
To focus on just the most-significant pathways, we can simply compare the distribution of p med values in the first bin to that in the remaining bins using a one-sided, non-parametric Wilcoxon test. These significance values are also shown in Table 3 . This less strict test is significant in all the pulmonary disease cases and almost all the DS ones as well. Both the tests and the plots support the conclusion that there is enrichment of alleviating genetic relationships between disease genes and pathway genes for the pathways whose p cent values are in the most significant decile.
Although there are many issues with the data used to produce these results, the conservation of genetic interactions across species being one of the most salient, the trends shown here add systematic evidence to the anecdotal evidence above that this approach can indeed find pathways playing a mediating role in disease processes, potentially leading to the discovery of novel therapeutic interventions. Such an approach may be applied in the context of any disease or phenotype of interest.
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